Specialty Pharma Journal Specialty, Precision & Technology
NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that new interim data show that 80% of infants (8 out of 10) with rapidly progressive lysosomal acid lipase deficiency (LAL-D) treated with Kanuma® (sebelipase alfa) survived beyond 1 year of age.1 Patients also benefited from improvements in a number of …
Tag Archives: Kanuma
November, 2017
December, 2015
-
8 December
FDA Approves Alexion’s Kanuma for Patients with a Rare Enzyme Disease
CHESHIRE, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced today that the U.S. Food and Drug Administration (FDA) has approved Kanuma™(sebelipase alfa) for the treatment of patients of all ages with a diagnosis of lysosomal acid lipase deficiency (LAL-D). Kanuma, an innovative enzyme replacement therapy (ERT), is the first therapy approved …
May, 2015
-
6 May
Alexion Enhances its Rare Disease Business Acquiring Synageva for $8.4 Billion
Rare disease company Alexion Pharmaceuticals, Inc. agreed to acquire smaller rival Synageva BioPharma Corp for $8.4 billion in cash and stock, more than double its market value. The companies announced today that they have entered into a definitive agreement, under which Alexion will acquire Synageva for consideration for $115 in …